FreeCME

Live CME Webcasts Improving Outcomes for Alopecia Areata

/ Print /
| ShareMore
/ Text Size +
8/3/22 4:30 pm to 8/11/22 8:30 pm EDT

alopeciaAreata.png


Description:

Alopecia areata (AA) is a form of nonscarring hair loss. While not life-threatening or painful, its cosmetic manifestations have profound negative influence on patients’ psychological status and relationships. There are no specific systemic therapies approved for AA, and the condition is currently managed with a variety of off-label options that provide variable efficacy and potential risky adverse effects. An improved understanding of disease etiology has led to the development of new therapies that target pathological pathways involved in AA, including the Janus kinase (JAK)/signal transducer and activator of transcription signaling pathway. This webinar will review the clinical manifestations and assessment of AA, along with clinical trial results with oral JAK inhibitors, which are showing promise. This program has been created for US dermatology allied healthcare professionals (HCPs) and will include several interactive case study discussions.

Learning Objectives:

The learning objectives of this event are:

  • Identify the clinical manifestations, associated autoimmune disorders, and psychosocial burden of AA
  • Review the epidemiology and risk factors associated with AA
  • Identify immunologic pathways involved in the pathogenesis of AA
  • Explain the mechanism of action of emerging systemic therapies for AA, focusing on JAK inhibition
  • Assess the target specificity and benefits/risks of emerging JAK inhibitors and other drug classes for AA
  • Identify clinical considerations for the potential use of emerging therapies specific to AA

Date/Time Details:

Wednesday, August 3, 2022

4:00pm – 5:30 pm Eastern Time

Live Webcast


Thursday, August 11, 2022

7:00pm - 8:30 pm Eastern Time

Live Webcast


Target Audience

This initiative is intended for US dermatology allied HCPs, including physician assistants, nurse practitioners, and nurses, as well as other allied HCPs who may be involved in the management of patients with AA.


Brett King, MD, PhD
 Associate Professor of Dermatology
 Yale School of Medicine
 New Haven, CT

BrettKing.jpg


Sharna Givans, DNP, APRN, FNP-BC 
 Tampa, FL

SharnaKing.png


Douglas DiRuggiero, DMSc, PA-C
 Skin Cancer and Cosmetic Dermatology Center
 Rome, GA

DouglasDiRuggiero.png

 
AKHsmall.jpg Credit provided by AKH Inc., Advancing Knowledge in Healthcare


In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Catalyst Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


 PA_logo.png Physician Assistants
 
AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Nurses
 1.5 ANCC contact hours.

Nurse Practitioners

AANP_logo.jpg

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and Catalyst Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803.
 
This activity is approved for 1.5 contact hour(s) (which includes 0.5 hour(s) of pharmacology).

Commercial Support:
 This activity is supported by an educational grant from Pfizer, Inc.

Criteria for Success
Certificates of completion will be awarded based on the participant’s attendance and submission of the activity evaluation/claim credit form. You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this activity, please contact AKH Inc. at tbrignoni@akhcme.com.